TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

Slides:



Advertisements
Similar presentations
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters by Maha El-Zimaity, Rima Saliba, Kawah Chan, Munir Shahjahan,
The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Gupta V, Tallman MS, Weisdorf DJ
Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation by Jan Moritz Middeke,
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,
Solid cancers after allogeneic hematopoietic cell transplantation
Nonmyeloablative conditioning for relapsed follicular lymphoma
Superior Survival after Autologous vs
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,
Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative.
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia:
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Functional neutrophils from human ES cells
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission  Jennifer L. Holter.
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission 
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.
Biology of Blood and Marrow Transplantation
Volume 21, Issue 3, Pages e4 (September 2017)
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report.
Biology of Blood and Marrow Transplantation
Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced.
Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark.
Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis  Christina.
Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia 
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in.
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation by Wenbin Xiao, Maheetha.
by Kaiwen Chen, Matthew P. Cheng, Sarah P
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report.
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma  Eric Smith, Sean M. Devlin, Satyajit.
Biology of Blood and Marrow Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes  Bartlomiej M. Getta, Ashwin Kishtagari,
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving.
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 by Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri,
Adenovirus Viremia in Adult CD34+ Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact  Yeon Joo Lee, Yao-Ting Huang,
Bridge to transplant following Bv+Bs regimen.
Treatment versus Transplant for Challenging Hematologic Disorders
Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis by Juliet N. Barker, Kirsten Boughan, Parastoo.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
by Jan J. Cornelissen, and Didier Blaise
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS:
by Lapo Alinari, and Kristie A. Blum
Presentation transcript:

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh, Catherine C. Coombs, Sean Devlin, Maria Arcila, Abhinita Mohanty, Ross L. Levine, Martin S. Tallman, Ann A. Jakubowski, Sergio A. Giralt, and Alan M Hanash Blood Volume 128(22):3481-3481 December 2, 2016 ©2016 by American Society of Hematology

Bartlomiej M Getta et al. Blood 2016;128:3481 ©2016 by American Society of Hematology

Bartlomiej M Getta et al. Blood 2016;128:3481 ©2016 by American Society of Hematology

Bartlomiej M Getta et al. Blood 2016;128:3481 ©2016 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.